Take­da signs off on a $2B deal aimed at by­pass­ing AAV road­blocks on the way to gene ther­a­py 2.0

Take­da has tak­en an­oth­er step down the road to build­ing up its gene ther­a­py plat­form.

The phar­ma gi­ant an­nounced Tues­day morn­ing that it’s struck the lat­est in a se­ries of deals with one of the up­starts in the field to ex­plore new de­signs for de­liv­ery ve­hi­cles — look­ing to go far past the AAV pro­to­types that have dri­ven the field so far.

The spot­light to­day falls on Code Bio­ther­a­peu­tics, a pri­vate start­up run by ex-GSK BD chief Bri­an McVeigh.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER